GoHealth (NASDAQ:GOCO) had its price target dropped by investment analysts at Morgan Stanley from $14.00 to $13.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 24.40% from the company’s current price.
Several other brokerages have also commented on GOCO. Evercore ISI cut their price objective on GoHealth from $27.00 to $25.00 and set an “outperform” rating for the company in a report on Thursday, November 12th. Zacks Investment Research downgraded GoHealth from a “hold” rating to a “sell” rating in a research note on Tuesday, January 12th. Raymond James reaffirmed a “buy” rating on shares of GoHealth in a research report on Thursday, November 12th. Finally, Credit Suisse Group dropped their price objective on shares of GoHealth from $21.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company’s stock. GoHealth presently has an average rating of “Buy” and an average target price of $20.00.
Shares of NASDAQ:GOCO opened at $10.45 on Wednesday. GoHealth has a 1 year low of $10.01 and a 1 year high of $26.25. The stock’s fifty day moving average price is $14.13 and its 200-day moving average price is $13.31.
GoHealth (NASDAQ:GOCO) last issued its earnings results on Monday, March 8th. The company reported $0.41 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.46 by ($0.05). The business had revenue of $445.90 million during the quarter, compared to analyst estimates of $435.31 million. The firm’s revenue for the quarter was up 54.5% on a year-over-year basis. On average, research analysts predict that GoHealth will post -0.28 earnings per share for the current fiscal year.
In other news, COO Shane E. Cruz sold 113,171 shares of the business’s stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $15.02, for a total transaction of $1,699,828.42. Following the transaction, the chief operating officer now owns 113,171 shares of the company’s stock, valued at approximately $1,699,828.42. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Shane E. Cruz sold 11,829 shares of the stock in a transaction on Wednesday, January 27th. The shares were sold at an average price of $15.02, for a total transaction of $177,671.58. Following the completion of the sale, the chief operating officer now directly owns 75,000 shares in the company, valued at approximately $1,126,500. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 346,000 shares of company stock valued at $5,162,580.
A number of institutional investors have recently bought and sold shares of GOCO. Cubist Systematic Strategies LLC bought a new stake in GoHealth in the third quarter worth about $41,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of GoHealth in the fourth quarter worth approximately $87,000. Point72 Europe London LLP bought a new stake in shares of GoHealth during the 3rd quarter worth approximately $130,000. Arizona State Retirement System purchased a new position in GoHealth during the 4th quarter valued at $167,000. Finally, Sei Investments Co. purchased a new position in GoHealth during the 3rd quarter valued at $165,000. 26.55% of the stock is currently owned by institutional investors.
As a leading health insurance marketplace, GoHealth’s mission is to improve access to healthcare in America. Enrolling in a health insurance plan can be confusing for customers, and the seemingly small differences between plans can lead to significant out-of-pocket costs or lack of access to critical medicines and even providers.
Recommended Story: Discover Your Risk Tolerance
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]